CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Fintel reports that on November 12, 2025, Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +11.36% and -86.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...
CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...
Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?
Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback